Mounjaro vs Ozempic: An Honest Comparison

If you are comparing these two for weight loss, start with the fact that decides almost everything else: neither Mounjaro nor Ozempic is FDA-approved for weight loss. Both are type 2 diabetes medications. The weight-management versions are different brands of the same molecules.

First, clear up the names

There are two molecules here and four brand names.

Molecule	Diabetes brand	Weight-management brand
Tirzepatide	Mounjaro	Zepbound
Semaglutide	Ozempic	Wegovy

Mounjaro and Zepbound contain the same drug. Ozempic and Wegovy contain the same drug. What differs is the approved indication on the label, and that determines who can be prescribed it, what dose range is available, and — most importantly — what insurance will pay for.

This is why “Mounjaro vs Ozempic for weight loss” is a slightly wrong question. If weight management is the goal and you do not have type 2 diabetes, the on-label comparison is Zepbound vs Wegovy.

The head-to-head trial

These two were compared directly in SURPASS-2, published in the New England Journal of Medicine: 1,879 adults with type 2 diabetes on metformin, randomised to tirzepatide or semaglutide 1 mg for 40 weeks. Mean baseline A1C was 8.28%.

At 40 weeks	Tirzepatide (5/10/15 mg)	Semaglutide 1 mg
A1C reduction	2.01 / 2.24 / 2.30 points	1.86 points
A1C back under 5.7%	51% (at 15 mg)	20%
Additional weight loss	1.9–5.5 kg more	—

Tirzepatide was superior on both A1C and weight.

The caveat that matters: the comparison used semaglutide 1 mg, which is not the maximum Ozempic dose — 2 mg is also approved. A trial against the higher dose would likely narrow the gap, though it is unlikely to close it. Treat “tirzepatide is better” as well-supported but not as large as the headline suggests.

The indications now differ in an important way

Both labels have expanded, and this is the part that changes fastest.

Ozempic is approved for glycaemic control in type 2 diabetes, for cardiovascular risk reduction in type 2 diabetes with established cardiovascular disease, and — since January 2025 — to reduce the risk of worsening kidney disease, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. That came from the FLOW trial, which showed a 24% relative risk reduction on its composite endpoint.

Mounjaro is approved for glycaemic control in type 2 diabetes and, since 28 August 2026, to reduce the risk of cardiovascular death, non-fatal heart attack and non-fatal stroke in adults with type 2 diabetes at high cardiovascular risk. That came from SURPASS-CVOT, which compared it against dulaglutide in over 13,000 participants.

So as of now: both carry a cardiovascular indication in type 2 diabetes, and only Ozempic carries a kidney indication. If you have type 2 diabetes with chronic kidney disease, that is a genuine, label-level difference worth raising with your clinician.

Approval and access

Because neither is approved for weight management, prescribing either purely for weight loss is off-label. That is legal and clinicians do it, but it has consequences worth knowing:

• Insurance rarely covers off-label weight-loss use. Coverage usually follows the indication, so a plan that covers Ozempic for diabetes may decline it for weight loss.
• Manufacturer savings programmes are usually tied to the approved indication too.
• The weight-management brands exist precisely to solve this. If weight is the goal, Wegovy and Zepbound are the on-label route and generally the one that gets covered.

Supply has also been volatile for these brands. Check current availability rather than assuming.

Cost

With diabetes as the indication and insurance coverage, cost is usually manageable and driven by your formulary.

Paying cash is a different picture. As of our September 2026 price check, telehealth self-pay pricing commonly starts around $149/month for oral semaglutide options and $199/month for the Wegovy pen, with tirzepatide-based options generally higher, around $299/month. Membership fees are typically charged on top. Our all-in cost calculator works out the 12-month figure, which is the number that actually matters once dose escalation is included.

How to actually decide

These are questions for your appointment, not a recommendation:

1. Do I have type 2 diabetes? If not, the relevant comparison is Zepbound vs Wegovy, not this one.
2. Do I have chronic kidney disease alongside diabetes? Only Ozempic currently carries that indication.
3. What does my formulary cover, and for which indication?
4. What is the 12-month cost including dose escalation, not the first month?
5. What does my clinician advise given my A1C, kidney function, cardiovascular history and other medications?

Educational content only. This is not medical advice, and nothing here should be used to start, stop, or switch a medication — that belongs with a licensed prescriber who knows your history.